噻托溴铵干粉吸入在慢性阻塞性肺疾病序贯治疗中的应用  

THE APPLICATION OF TIOTROPIUM IN THE SEQUENTIAL THERAPY FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE

作　　者：林武强[1] 吴卫锋[1] 林增锐[1] 

机构地区：[1]揭阳市人民医院,广东揭阳522000

出　　处：《现代医院》2011年第2期34-36,共3页Modern Hospitals

摘　　要：目的探讨噻托溴铵干粉吸入在慢性阻塞性肺疾病急性加重症状控制后应用的疗效和安全性。方法将60例肺功能为中度(GOLDⅡ级,FEV1/FVC<70%,50%≤FEV1<80%预计值)的COPD病人随机分为两组,治疗组应用噻托溴铵干粉吸入,对照组使用异丙托溴铵定量气雾剂,治疗12个月,在第1个月、第6个月、第12个月,分别行肺功能检查,测FEV1和FVC,同时记录12个月内急性加重次数。结果治疗组第一秒用力呼气容积(FEV1)、用力肺活量(FVC)、FEV1占预计值的百分比上升值及急性加重次数较对照组有显著性差异(p<0.05);治疗组的常见不良反应为口干(6%),无其他不适。结论噻托溴铵对于肺功能为中度的COPD患者疗效显著且安全可靠。Objective To investigate the efficacy and safety of tiotropium bromide in treating chronic obstructive pulmonary disease （ COPD ）. Methods 60patients was randomly divided into the treatment group （ 30 cases ） and control group （30 cases）, the treatment group was treated with tiotropium bromide, and the control group was treated with ipratropium. The spirometry was conducted at 1 month ,6 months and 12months after treatment and record the times of acute exacerbations in 12 months. Results Forced expiratory volume in one second（ FEV1 ） ,forced vital capacity（ FVC）, FEVI/Pred% and times of acute exacerbations were significantly better after treatment in the tiotropium groups （p 〈0.05 ）. The major adverse event was dry mouth（6% ） ;no other bad effect was reported. Conclusion Tiotropium.bromide is an effective and safe bronchodilator in the treating moderate COPD patients.

关 键 词：噻托溴铵 序贯治疗 慢性阻塞性肺疾病肺功能 

分 类 号：R563[医药卫生—呼吸系统]